newsfilter
← Latest News
GlobeNewswire·

Portage Biotech Announces Results for Fiscal Quarter Ended June 30, 2022

--Robust Pipeline Now Includes Five Clinical-Stage Small Molecule Immuno-Oncology Assets, Including Invariant Natural Killer T Cell (iNKT) Agonists and Adenosine Antagonists-- ---Cash Runway for New and Current Programs Potentially Extended into 2024-